Neoplasms – Talk Bio

Genmab Abandons ADC Asset Acquired in $1.8B ProfoundBio Deal

1 day ago talkbio0Tagged Acquisition, ADC, Antibody-Drug Conjugates, Genmab, Neoplasms, ProfoundBio, therapeutic autologous dendritic cells

Genmab; ProfoundBio; antibody-drug conjugates; ADC; acquisition; oncology; Rina-S

Appia Bio Shuts Down Before Reaching Clinical Trials Amid Biotech Funding Crunch

3 weeks ago talkbio0Tagged Appia Bio, biotech closures, Cell Therapy, Clinical Trials, Indonesian language, Kite Pharma partnership, Neoplasms

Appia Bio; cell therapy; biotech shutdown; funding challenges; clinical trials; Kite Pharma partnership; oncology; biotech closures; IND application

VantAI and Halda Strike $1B+ AI-Driven Partnership on ‘Hold-and-Kill’ Drugs

4 weeks ago talkbio0Tagged Aortic Valve Insufficiency, cellular targeting, Chimera organism, Drug Discovery, Halda Therapeutics, hold-and-kill, Immunology, Induce (action), Neoplasms, Proximity, RIPTAC, target-effector pairs, VantAI

VantAI; Halda Therapeutics; RIPTAC drugs; hold-and-kill; AI drug discovery; target-effector pairs; oncology; immunology; regulated induced proximity targeting chimeras; $1 billion deal

Bayer-allied NextRNA Therapeutics winds down operations after missing a milestone in their collaboration

1 month ago talkbio0Tagged Bayer, Dana-Farber, Funding, Long Intergenic Non-Protein Coding RNA, Massachusetts biotech, missed milestone, Neoplasms, NextRNA, Plant seeds, Series, shutdowns

NextRNA Therapeutics; Bayer; lncRNA; long non-coding RNA; oncology; biotech wind-down; missed milestone; Massachusetts biotech; seed and Series A funding; Dana-Farber; Carl Novina; 2025 biotech shutdowns

Minghui Raises $131M to Advance PD-1xVEGF Bispecific Antibody Program

1 month ago talkbio0Tagged Chinese biotech, Clinical Development, Inhibitor, Janus kinase, Minghui, Neoplasms, PD-1xVEGF bispecific, pre-IPO ', therapeutic autologous dendritic cells, trials

Minghui; Chinese biotech; PD-1xVEGF bispecific; fundraising; pre-IPO; ADC trials; JAK inhibitor; oncology; clinical development

XtalPi and DoveTree Announce Landmark $6 Billion AI-Powered Drug Discovery Collaboration

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Collaboration, Dosage Forms, DoveTree Medicines, Drug Discovery, Gregory Verdine, Immunology, Metabolic Diseases, milestone payments, Neoplasms, Neurology speciality, Robotics, royalties, upfront payment, XtalPi

XtalPi; DoveTree Medicines; AI drug discovery; robotics; pharmaceutical R&D; Gregory Verdine; oncology; immunology; neurology; metabolic diseases; collaboration; upfront payment; milestone payments; royalties

Y-mAbs Therapeutics Acquired by SERB Pharmaceuticals in $412 Million Buyout Following Strategic Review

1 month ago talkbio0Tagged all-cash tender, Danyelza, Infrequent, Merger, Neoplasms, pharmaceutical acquisition, Serbs, strategic review, Y-mAbs

Y-mAbs Therapeutics; SERB Pharmaceuticals; buyout; Danyelza; rare oncology; merger; pharmaceutical acquisition; strategic review; all-cash tender offer

Clinical Roundup: Cardiff, VYNE and NewAmsterdam Report Key Trial Results in Multiple Disease Areas

2 months ago talkbio0Tagged Alzheimer 's disease, BROADWAY trial, Cardiff Oncology, Clinical Trials, Metastasis from malignant neoplasm of colon and/or rectum, Neoplasms, NewAmsterdam Pharma, onvansertib, Statistical Significance, Vyne

Cardiff Oncology; VYNE; NewAmsterdam Pharma; clinical trial updates; onvansertib; metastatic colorectal cancer; Alzheimer’s disease; BROADWAY trial; oncology; statistically significant results